Table 2.
Baseline characteristics of the subgroups
| Variable | EPBD (n = 77) | EST (n = 73) | Neither EPBD nor EST (n = 68) | ||||||
| G1a (n = 41) | G2a (n = 36) | P value | G1b (n = 34) | G2b (n = 39) | P value | G1c (n = 38) | G2c (n = 30) | P value | |
| Age (yr) | 59.6 ± 9.7 | 59.3 ± 10.4 | 0.8963 | 58.4 ± 10.1 | 59.9 ± 10.9 | 0.5419 | 61.4 ± 9.9 | 56.9 ± 10.1 | 0.0559 |
| Sex, male/female | 21/20 | 24/12 | 0.1700 | 23/11 | 25/14 | 0.7502 | 24/14 | 22/8 | 0.3732 |
| Presence of gallstones (n) | 4 | 2 | 0.7948 | 5 | 4 | 0.8259 | 4 | 3 | 0.7407 |
| History of cholecystectomy (n) | 3 | 3 | 0.7948 | 2 | 4 | 0.8013 | 2 | 2 | 0.7835 |
| Total leukocyte count (× 109/L) | 5.9 ± 1.9 | 6.0 ± 2.2 | 0.8321 | 5.4 ± 2.3 | 5.9 ± 2.1 | 0.3347 | 5.8 ± 1.7 | 6.1 ± 2.4 | 0.5304 |
| Amylase (U/L) | 84.5 ± 23.4 | 89.2 ± 24.7 | 0.3932 | 89.1 ± 25.6 | 87.1 ± 27.2 | 0.7464 | 87.3 ± 26.2 | 92.0 ± 27.2 | 0.4526 |
| TB (mg/dL) | 4.7 ± 1.1 | 4.6 ± 0.9 | 0.6736 | 4.1 ± 0.7 | 3.9 ± 0.9 | 0.2863 | 3.6 ± 0.9 | 3.7 ± 1.0 | 0.6465 |
| ALT (IU/L) | 127.4 ± 35.1 | 118.9 ± 33.4 | 0.2766 | 123.1 ± 33.1 | 125.1 ± 37.4 | 0.8085 | 117.9 ± 31.4 | 113.9 ± 32.7 | 0.5943 |
| AST (IU/L) | 100.6 ± 29.3 | 101.6 ± 24.1 | 0.8716 | 97.9 ± 24.3 | 100.7 ± 24.9 | 0.6273 | 98.1 ± 21.3 | 103.7 ± 24.1 | 0.2919 |
| Prothrombin time (s) | 12.3 ± 1.9 | 11.9 ± 2.3 | 0.4093 | 10.3 ± 1.7 | 10.9 ± 2.0 | 0.1659 | 11.3 ± 1.8 | 11.6 ± 1.7 | 0.4661 |
| Platelet count (× 106/L) | 139.2 ± 44.1 | 142.1 ± 38.4 | 0.7577 | 143.5 ± 40.1 | 146.1 ± 41.3 | 0.7852 | 147.5 ± 39.1 | 153.5 ± 42.1 | 0.5280 |
| Maximum diameter of CBD (mm) | 11.5 ± 2.3 | 12.1 ± 2.1 | 0.2316 | 12.3 ± 2.0 | 12.9 ± 1.9 | 0.1907 | 11.7 ± 1.8 | 12.5 ± 2.1 | 0.0797 |
EPBD: Endoscopic papillary balloon dilatation; EST: Endoscopic sphincterotomy; TB: Total serum bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CBD: Common bile duct.